Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The enzyme poly-ADP-ribose-polymerase (PARP) mediates DNA-repair and rearrangements of the nuclear chromatin. Generally, PARP activity is thought to promote cell survival and in recent years a number of PARP inhibitors have been clinically developed for cancer treatment. Paradoxically, PARP activity is also connected to many diseases including the untreatable blinding disease Retinitis Pigmentosa (RP), where PARP activity appears to drive the pathogenesis of photoreceptor loss. We tested the efficacy of three different PARP inhibitors to prevent photoreceptor loss in the rd1 mouse model for RP. In retinal explant cultures in vitro, olaparib had strong and long-lasting photoreceptor neuroprotective capacities. We demonstrated target engagement by showing that olaparib reduced photoreceptor accumulation of poly-ADP-ribosylated proteins. Remarkably, olaparib also reduced accumulation of cyclic-guanosine-monophosphate (cGMP), a characteristic marker for photoreceptor degeneration. Moreover, intravitreal injection of olaparib in rd1 animals diminished PARP activity and increased photoreceptor survival, confirming in vivo neuroprotection. This study affirms the role of PARP in inherited retinal degeneration and for the first time shows that a clinically approved PARP inhibitor can prevent photoreceptor degeneration in an RP model. The wealth of human clinical data available for olaparib highlights its strong potential for a rapid clinical translation into a novel RP treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, intravitreal injection of the PARP inhibitor, olaparib, has shown promising neuroprotective effect in mouse models of IRDs (Sahaboglu et al., 2016).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Sahaboglu et al., 2016
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
Kriaucionis, S., & Heintz, N. (2009) · Science · doi:10.1126/science.1169786 · Cited by 2,700
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
The Major Cell Populations of the Mouse Retina
Jeon, C.-J., Strettoi, E., & Masland, R. H. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-21-08936.1998 · Cited by 1,429
Bowes, C., Li, T., Danciger, M., Baxter, L. C., Applebury, M. L., & Farber, D. B. (1990) · Nature · doi:10.1038/347677a0 · Cited by 852
Poly(ADP-Ribose) in the Cellular Response to DNA Damage
Berger, N. A. (1985) · Radiation Research · doi:10.2307/3576299 · Cited by 775
Unexpected low‐dose toxicity of the universal solvent DMSO
Galvao, J., Davis, B., Tilley, M., Normando, E., Duchen, M. R., & Cordeiro, M. F. (2014) · The FASEB Journal · doi:10.1096/fj.13-235440 · Cited by 739
Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Langelier, M.-F., Planck, J. L., Roy, S., & Pascal, J. M. (2012) · Science · doi:10.1126/science.1216338 · Cited by 665
Regulated necrosis: disease relevance and therapeutic opportunities
Conrad, M., Angeli, J. P. F., Vandenabeele, P., & Stockwell, B. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.6 · Cited by 630
McLaughlin, M. E., Sandberg, M. A., Berson, E. L., & Dryja, T. P. (1993) · Nature Genetics · doi:10.1038/ng0693-130 · Cited by 596
Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities
Fatokun, A. A., Dawson, V. L., & Dawson, T. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12416 · Cited by 594
Research works printed but not linked: 1
- Wei, T. et al. Generation and functional characterization of a transgenic mouse expressing a Ca2+ biosensor in cone photoreceptors. J. Neurosci. 32, 6994–6981 (2012).
Cited by
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies
Olivares-González, L., Velasco, S., Campillo, I., & Rodrigo, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042096 · Cited by 128
Cellular mechanisms of hereditary photoreceptor degeneration – Focus on cGMP
Power, M., Das, S., Schütze, K., Marigo, V., Ekström, P. A. R., & Paquet‐Durand, F. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.005 · Cited by 128
Self-citationDynamic lipid turnover in photoreceptors and retinal pigment epithelium throughout life
Lewandowski, D., Sander, C. L., Tworak, A., Gao, F., Xu, Q., & Skowronska‐Krawczyk, D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101037 · Cited by 117
Sphingolipids as critical players in retinal physiology and pathology
Simón, M. V., Basu, S. K., Qaladize, B., Grambergs, R. C., Rotstein, N. P., & Mandal, N. A. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr120000972 · Cited by 99
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
Tolone, A., Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2019) · Genes · doi:10.3390/genes10060453 · Cited by 51
“A number of cell death-related processes have been discovered down-stream of cGMP-signaling, including excessive activation of histone-deacetylase [80], calpain-type proteases [81], DNA-methyl-transferase [82] and poly-ADP-ribose-polymerase (PARP) [83,84].”
BackgroundSelf-citationTrakkides, T.-O., Schäfer, N., Reichenthaler, M., Kühn, K., Brandwijk, R. J. M. G. E., Toonen, E. J. M., Urban, F., Wegener, J., Enzmann, V., & Pauly, D. (2019) · Antioxidants · doi:10.3390/antiox8110548 · Cited by 56
Kovács, K., Váczy, A., Fekete, K., Kovari, P., Atlasz, T., Reglődi, D., Gabriel, R., Gallyas, F., & Sümegi, B. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25936 · Cited by 39
Ceramide Induces the Death of Retina Photoreceptors Through Activation of Parthanatos
Spalm, F. H. P., Vera, M. S., Dibo, M., Simón, M. V., Politi, L. E., & Rotstein, N. P. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1402-4 · Cited by 36
Power, M., Rogerson, L. E., Schubert, T., Berens, P., Euler, T., & Paquet‐Durand, F. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24807 · Cited by 35
Self-citationPoly ADP ribosylation and extracellular vesicle activity in rod photoreceptor degeneration
Vidal‐Gil, L., Sancho-Pellúz, J., Zrenner, E., Oltra, M. R., & Sahaboglu, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-40215-3 · Cited by 35
Self-citationZhang, L., Chen, C. Y., Fu, J., Lilley, B. N., Berlinicke, C. A., Hansen, B. S., Ding, D., Wang, G., Wang, T., Shou, D., et al. (2021) · eLife · doi:10.7554/elife.57245 · Cited by 35
“For PARP, chemical inhibitors and a knock out line provided further confirmation (Jiao et al., 2016; Paquet-Durand et al., 2007; Sahaboglu et al., 2017, 2016, 2010).”
BackgroundOlivares‐González, L., Velasco, S., Campillo, I., Salom, D., García, E. G., Soriano, J. M., & Rodrigo, R. (2021) · Antioxidants · doi:10.3390/antiox10071033 · Cited by 34
“In particular, PARP inhibitors reduced cell death and microglial activation in RP models [105,106].”
BackgroundSahaboglu, A., Sharif, A. M., Feng, L., Secer, E., Zrenner, E., & Paquet‐Durand, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181374 · Cited by 29
Self-citationYan, J., Chen, Y., Zhu, Y., & Paquet‐Durand, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910567 · Cited by 24
Self-citationDrug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration
Sahaboglu, A., Miranda, M., Canjuga, D., Avci‐Adali, M., Savytska, N., Secer, E., Pliego, J. A. F., Kayık, G., & Durdağı, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03283-2 · Cited by 28
Self-citationIn vitro Model Systems for Studies Into Retinal Neuroprotection
Zhu, Y., Cao, B., Tolone, A., Yan, J., Christensen, G., Arango‐González, B., Ueffing, M., & Paquet‐Durand, F. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.938089 · Cited by 30
Self-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Early clinical evidence further supports the use of immunomodulation to prevent and treat GTAU in the context of IRDs, discussed below.”
InfluentialA retinal model of cerebral malaria
Paquet‐Durand, F., Beck, S. C., Das, S., Huber, G., Chang, L., Schubert, T., Tanimoto, N., Garrido, M. G., Mühlfriedel, R. L., Bolz, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39143-z · Cited by 20
Self-citationInherited Retinal Degeneration: PARP-Dependent Activation of Calpain Requires CNG Channel Activity
Yan, J., Günter, A., Das, S., Mühlfriedel, R., Michalakis, S., Jiao, K., Seeliger, M. W., & Paquet‐Durand, F. (2022) · Biomolecules · doi:10.3390/biom12030455 · Cited by 16
Self-citationMoshtaghion, S. M., Caballano‐Infantes, E., Reyes, Á. P., Valdés-Sánchez, L., Fernández, P. G., de la Cerda, B., Riga, M. S., Álvarez‐Dolado, M., Peñalver, P., Morales, J. C., et al. (2024) · Antioxidants · doi:10.3390/antiox13020201 · Cited by 18
“Since parthanatos is characterized by the overactivation of PARP1, specific inhibitors of this DNA repair protein have been tested to avoid photoreceptor degeneration [15–17].”
BackgroundAntibody drug conjugates: Development, characterization, and regulatory considerations
Kommineni, N., Pandi, P., Chella, N., Domb, A. J., & Khan, W. (2019) · Polymers for Advanced Technologies · doi:10.1002/pat.4789 · Cited by 21
Fluorescent detection of PARP activity in unfixed tissue
Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245369 · Cited by 12
“Even further, PARP inhibition, in vitro and in vivo, resulted in increased photoreceptor survival [13, 17].”
BackgroundSelf-citationSinha, A., Katyal, S., & Kauppinen, T. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108502 · Cited by 16
Reduced nuclear NAD+ drives DNA damage and subsequent immune activation in the retina
Brown, E. E., Scandura, M. J., Mehrotra, S., Wang, Y., Du, J., & Pierce, E. A. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab324 · Cited by 13
Belhadj, S., Hermann, N. S., Zhu, Y., Christensen, G., Straßer, T., & Paquet‐Durand, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073892 · Cited by 10
“5), which is in accordance with previous studies (Sahaboglu et al. 2016).”
ResultSelf-citationYang, Y., Wu, J., Lu, W., Dai, Y., Zhang, Y., & Sun, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.925835 · Cited by 17
“We also tested a lower dose (100 nM) of olaparib as previously reported (Sahaboglu et al., 2016) and found no protective effects on PhNR (Supplementary Figure S4).”
BackgroundResultDong, Y., Yan, J., Yang, M., Xu, W., Hu, Z., Paquet‐Durand, F., & Jiao, K. (2023) · Biomolecules · doi:10.3390/biom13040581 · Cited by 11
“In a previous study, we found 5-methylcytosine (5mC) to accumulate in rd1 photoreceptors and that inhibition of DNA methyltransferases (DNMTs) with the drug decitabine reduced photoreceptor cell death [26].”
BackgroundSelf-citationDong, Y., Yan, J., Xu, W., Paquet‐Durand, F., Hu, Z., & Jiao, K. (2023) · PeerJ · doi:10.7717/peerj.15659 · Cited by 13
Self-citationPöstyéni, E., Szabadfi, K., Sétáló, G., & Gabriel, R. (2021) · Cells · doi:10.3390/cells10123470 · Cited by 13
“Pharmacological inhibition of PARP offers protection during photoreceptor degeneration in reti itis pigmentosa [27,28], hypoxia-induced ischemic injury [19], hyperfusion-induce neurodegeneration [29] and diabetic retinal complication [30,31] in the retina.”
BackgroundPARP inhibitor rescues hearing and hair cell impairment in Cx26‐null mice
Wang, X., Chen, S., Qiu, Y., Xu, K., Bai, X., Xie, L., Kong, W., & Sun, Y. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20230066 · Cited by 10
Determining Photoreceptor Cell Identity: Rod Versus Cone Fate Governed by tbx2b Opposing nrl
Neil, G. J., Kluttig, K. H., & Allison, W. T. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.39 · Cited by 12
“Current treatments of many of these retinal degenerative diseases often focus primarily on the preservation of photoreceptors, 7,8 however, there is little that can be done currently to recover photoreceptor function once it has been lost.”
Release of Retinal Extracellular Vesicles in a Model of Retinitis Pigmentosa
Sahaboglu, A., Vidal‐Gil, L., & Sancho-Pellúz, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_71 · Cited by 10
Self-citationMbefo, M. K., Berger, A., Schouwey, K., Gérard, X., Kostic, C., Beryozkin, A., Sharon, D., Dolfuss, H., Munier, F. L., Tran, H. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179331 · Cited by 10
“[24], the authors estimated the half-life of olaparib to be eight minutes (which is a larger molecule than UNC1999), strongly supporting a rapid clearance of the EZH2 inhibitor.”
BackgroundInhibition of altered Orai1 channels in Müller cells protects photoreceptors in retinal degeneration
Sukkar, B., Oktay, L., Sahaboglu, A., Moayedi, A., Zenouri, S., al‐Maghout, T., Cantó, A., Miranda, M., Durdağı, S., & Hosseinzadeh, Z. (2023) · Glia · doi:10.1002/glia.24429 · Cited by 8
“The percentages of positive cells were assessed and calculated in a blinded fashion as reported previously (Sahaboglu et al., 2016).”
MethodSelf-citationTropitzsch, A. S., Müller, M. C., Paquet‐Durand, F., Mayer, F., Kopp, H., Schrattenholz, A. S., Müller, A., & Löwenheim, H. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00406 · Cited by 8
“, 2010), and PARP inhibitors, including the anti-cancer drug olaparib, improve retinal viability (Sahaboglu et al., 2016).”
BackgroundSelf-citationDeferiprone protects against photoreceptor degeneration by inhibiting parthanatos
Villarejo‐Zori, B., Zapata‐Muñoz, J., Sierra‐Filardi, E., Ramírez‐Pardo, I., Montava‐Garriga, L., Ganley, I. G., & Boya, P. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07686-x · Cited by 6
The role of epigenetic changes in the pathology and treatment of inherited retinal diseases
Miller, A. L., James, R. E., Harvey, A. R., Trifunović, D., & Carvalho, L. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1224078 · Cited by 7
“There was also a reduction in cGMP levels, thought to be an essential component of cell death in this model (Sahaboglu et al., 2016).”
BackgroundResultInfluentialMartín‐Guerrero, S. M., Casado, P., Muñoz‐Gámez, J. A., Carrasco, M., Navascués, J., Cuadros, M. Á., López‐Giménez, J. F., Cutillas, P. R., & Martín‐Oliva, D. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107790 · Cited by 6
Zhu, Y., Peiroten, L., Kumar, P. N., Hottin, C., Jiao, K., Haq, W., & Paquet‐Durand, F. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07901-9 · Cited by 5
Self-citationInherited Ocular Disease in the New Zealand Māori: Novel Genetic Mechanisms and Founder Effects
Vincent, A. L. (2018) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-13-0884-0_5 · Cited by 3
Zhu, Y., Fallatah, A. H. A., Jiao, K., Seeliger, M. W., & Paquet‐Durand, F. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70319 · Cited by 3
“Previous studies found that treatment with Ola—a PARP inhibitor that favors PARP-2 over PARP-1 (Table 1)—protected photoreceptors in the rd1 mouse model for recessive RP (Dong et al. 2023; Sahaboglu et al. 2016; Yan et al. 2022), but its effect on Rho I255del mutant retina was unclear.”
InfluentialSelf-citationSoto, T. B., Tenconi, P. E., Buzzi, E. D., Dionisio, L., Mateos, M. V., Rotstein, N. P., Spitzmaul, G. F., Politi, L. E., & German, O. L. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119816 · Cited by 2
Role of Nuclear NAD+ in Retinal Homeostasis
Brown, E. E., Scandura, M. J., & Pierce, E. A. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-27681-1_34 · Cited by 2
Zhu, Y., Kumar, P. N., Jiao, K., & Paquet‐Durand, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.666875 · Cited by 2
Self-citationPARP inhibition preserves cone photoreceptors in rd2 retina
Akkaya, P. N., Miranda, M., Almansa, I., Elmas, Ç., Trifunović, D., Hosseinzadeh, Z., & Sahaboglu, A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01982-5 · Cited by 2
“Indeed, we did not observe any protective effect of Olaparib on secondary cone degeneration in rd1 model, a primary rod degeneration model [36].”
InfluentialSelf-citationZhu, Y., Kumar, P. N., Jiao, K., & Paquet‐Durand, F. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02908-9 · Cited by 2
Self-citationMembers of Our Early Career Panel Highlight Key Research Articles On the Theme of Drug Repurposing
Miljković, F. N., Xiong, R., Sivakumar, D., & Brown, C. A. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0009 · Cited by 1
Zhu, Y., Fallatah, A. H. A., Jiao, K., Seeliger, M. W., & Paquet‐Durand, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671267 · Cited by 1
Self-citationSpinocerebellar Ataxia Type 7: From Mechanistic Pathways to Therapeutic Opportunities
Switonski, P. M., & Spada, A. R. L. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_17
Yan, J., Kong, L., Zhao, Z., Yang, Q., Wang, L., Yang, Q., Harteneck, C., Jiao, K., Hu, Z., & Paquet‐Durand, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.688383
Self-citationRole of the Glycogen Synthase Kinase 3 for the Retinal Development and Homeostasis
Braginskaja, E. (2018) · theses.fr (ABES) · doi:10.70675/72532a81z164ez4786z8c84zaf55afbdfa1d
“For example, olaparib, commonly used for cancer treatment, has shown promising neuroprotective effects in models of retinitis pigmentosa by inhibiting the activity of poly-ADP ribose polymerase (PARP) (Sahaboglu et al., 2016) (Jiao et al., 2016).”
Retinitis Pigmentosa: A Review of Its Pathogenesis and Emerging Molecular and Cellular Therapies
Tuli, N., Baeshen, M., Echbicheb, M., Kulbay, M., Ayalon, A., Ali, S. K., & Qian, C. X. (2026) · Vision · doi:10.3390/vision10040083
“Treatment with the clinically approved PARP inhibitor olaparib significantly reduced PARP activity, decreased cGMP accumulation, and delayed photoreceptor degeneration in mouse models of RP [218].”
Metadata
- Authors
- Sahaboglu, A., Barth, M., Secer, E., Amo, E. M. D., Urtti, A., Arsenijevic, Y., Zrenner, E., & Paquet-Durand, F.
- Affiliations
- University of Tübingen (DE)
- University of Eastern Finland (FI)
- University of Helsinki (FI)
- Corresponding author
- Sahaboglu, Ayse
- Venue
- Scientific Reports
- Published
- 2016-12-22
- Volume
- 6
- Issue
- 1
- Pages
- 39537-39537
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5177898
- OpenAlex
- W2561847233
- Cited by
- 53
- References
- 45
- Citations by year
- 2026: 1 · 2025: 9 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 10 · 2020: 3 · 2019: 12 · 2018: 3 · 2017: 1
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Työväentutkimus Vuosikirja (submittedVersion)
- IRIS (submittedVersion)
- Funders
- European Commission (304963)
- Deutsche Forschungsgemeinschaft (PA1751/7‐1, HEALTH-F2-2012-304963, SA3040/1-1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- olaparib, PARP inhibitors, retinitis pigmentosa, photoreceptor degeneration, rd1 mouse model, inherited retinal degeneration, poly(ADP-ribosyl)ation, cyclic GMP, intravitreal injection, retinal explant culture, DNA repair
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Animals, Cell Survival, Chromatin, Cyclic GMP, Immunohistochemistry, Mice, Inbred C3H, Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Binding, Rabbits, Retinal Degeneration, Neuroprotective Agents, Photoreceptor Cells, Vertebrate, Quantitative Structure-Activity Relationship, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.